文献速递类风湿关节炎

机器学习分析全血转录组识别甲氨蝶呤治疗类风湿关节炎疗效的生物标志物

Identifying biomarkers for methotrexate efficacy in rheumatoid arthritis: a machine learning approach to whole-blood transcriptomic analysis.
PubMed 文献 · Rheumatology (Oxford) · 2026-10-08

研究对100例未用过甲氨蝶呤的类风湿关节炎患者,在基线和治疗4周时采集全血进行RNA测序,用梯度提升树和SHAP值构建模型预测6个月MTX反应。基线和4周模型AUC分别为0.89和0.90,基线模型更稳定,应答者中CAV1、LCN12和GLB1L表达下调。结论提示全血转录组标志物可高置信度预测MTX反应,但需独立验证。

要点

  • 基线和4周全血转录组模型预测6个月MTX反应的AUC分别为0.89和0.90。
  • 基线模型SHAP值更稳定,可能更具泛化性。
  • 应答者基线CAV1、LCN12和GLB1L表达下调。

核心结论

  • 基线和4周MTX治疗后的全血基因表达谱可高置信度预测6个月治疗反应,但需独立验证。

研究设计与样本

  • 研究纳入100例未用过MTX的RA患者,在基线及MTX治疗4周后采集全血行RNA测序。
  • 采用梯度提升树训练机器学习模型,以6个月MTX反应为分类结局,并用SHAP值解释预测基因。

主要发现

  • 基于基线数据和4周数据训练的模型预测6个月MTX反应的AUC分别为0.89和0.90。
  • SHAP值稳定性显示基线模型总体更稳定,可能更具泛化性。
  • 基线关键预测基因包括CAV1、LCN12和GLB1L,这些基因在应答者中下调。

临床怎么用

  • 基线全血转录组标志物有望辅助RA早期治疗决策,支持精准医学 approach。
  • 当前结果需独立验证后方可用于临床预测MTX反应。

局限性

  • 研究结论明确指出现有发现需要独立验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Methotrexate (MTX) is the first-line treatment for rheumatoid arthritis (RA), yet inadequate response is reported in 30-40% of patients. Predicting MTX response early could enable more personalised and effective treatment. This study aimed to identify biomarkers predictive of MTX response at 6 months through whole-blood transcriptomic signatures using machine learning. METHODS: RNA-sequencing data were generated in whole-blood samples taken from 100 MTX-naïve RA patients at baseline (pre-treatment) and following 4-weeks post treatment with MTX. Machine learning models were trained to classify MTX response following 6-months of treatment using gradient boosted trees and interpreted using SHAP values to identify predictive genes. RESULTS: Machine learning models trained on baseline and 4-weeks data achieved AUCs of 0.89 and 0.90 respectively. Stability of SHAP values showed that the baseline model was generally more stable, and therefore potentially more generalisable. Key predictive genes at baseline, which were downregulated in responders, included CAV1, LCN12, and GLB1L. CONCLUSION: Blood-based gene expression profiling at baseline and after 4-weeks of MTX treatment can predict treatment response with high confidence revealing relevant gene pathways and candidate gene targets but requires independent validation. These findings highlight the potential for transcriptomic biomarkers to inform early treatment decision in RA, supporting precision medicine approaches.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yap CF, Nair N, Verstappen SMM, et al. Identifying biomarkers for methotrexate efficacy in rheumatoid arthritis: a machine learning approach to whole-blood transcriptomic analysis. Rheumatology (Oxford). 2026. PMID: 42850566. doi:10.1093/rheumatology/keag560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。